Anti-metastatic semi-synthetic sulfated maltotriose C-C linked dimers. synthesis and characterisation

Molecules

Volumn 17, Issue 8, 2012, Pages 9912-9930

  Vismara, Elena ^a   Coletti, Alessia ^a   Valerio, Antonio ^a   Naggi, Annamaria ^b   Urso, Elena ^b   Torri, Giangiacomo ^b  

^a POLITECNICO DI MILANO   (Italy)

^b Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

Author keywords

Heparin; Kink motif; Metastasis; NMR; Sulfated C O maltotriosyl dimers

Indexed keywords

ANTINEOPLASTIC AGENT; MALTOTRIOSE; SULFATE; TRISACCHARIDE;

ARTICLE; CHEMISTRY; DIMERIZATION; NUCLEAR MAGNETIC RESONANCE; SYNTHESIS;

ANTINEOPLASTIC AGENTS; DIMERIZATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; SULFATES; TRISACCHARIDES;

EID: 84865515232     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17089912     Document Type: Article

References (46)

1. Garg, H.G.; Linhardt, R.J.; Hales, C.A. Chemistry and Biology of Heparin and Heparan Sulfate; Elsevier: New York, NY, USA, 2005.
2. Rickles, F.R. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol. Haemost. Thromb. 2006, 35, 103-110.
3. Mousa, S.A. Anticoagulants in thrombosis and cancer: The missing link. Semin. Thromb. Hemost. 2002, 28, 45-52.
4. Jayson, G.C.; Gallagher, J.T. Heparin oligosaccharides: Inhibitors of the biological activity of bFGF on Caco-2 cells. Br. J. Cancer 1997, 75, 9-16.
5. Folkman, J.; Shing, Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv. Exp. Med. Biol. 1992, 313, 355-364.
6. Vlodavsky, I.; Mohsen, M.; Lider, O.; Svahn, C.M.; Ekre, H.P.; Vigoda, M.; Ishai-Michaeli, R.; Peretz, T. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invas. Metastas. 1994, 14, 290-302.
7. Borsig L.; Wong, R.; Feramisco, J.; Nadeau, D.R.; Varki, N.M.; Varki, A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl. Acad. Sci. USA 2001, 98, 3352-3357.
8. Stevenson, J.L.; Varki, A.; Borsig, L. Heparin attenuates metastasis mainly due to inhibition of Pand L-selectin, but non-anticoagulant heparins can have additional effects. Thromb. Res. 2007, 120 (Suppl. 2), S107-S111.
9. Nguyen, D.X.; Bos, P.D.; Massague, J. Metastasis: From dissemination to organ-specific colonization. Nat. Rev. Cancer 2009, 9, 274-284.
10. Parish, C.R.; Freeman, C.; Hulett, M.D. Heparanase: A key enzyme involved in cell invasion. Biochim. Biophys. Acta 2001, 1471, M99-M108, 2-7.
11. Barash, U.; Cohen-Kaplan, V.; Dowek, I.; Sanderson, R.D.; Ilan, N.; Vlodavsky, I. Proteoglycans in health and disease: New concepts for heparanase function in tumor progression and metastasis. FEBS J. 2010, 277, 3890-3903.
12. Levy-Adam, F.; Ilan, N.; Vlodavsky, I. Tumorigenic and adhesive properties of heparanase. Semin. Cancer Biol. 2010, 20, 153-160.
13. Arvatz, G.; Shafat, I.; Levy-Adam, F.; Ilan, N.; Vlodavsky, I. The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metast. Rev. 2011, 30, 253-268.
14. Ferro, V.; Hammond, E.; Fairweather, J.K. The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev. Med. Chem. 2004, 4, 693-702.
15. Bar-Ner, M.; Eldor, A.; Wasserman, L.; Matzner, Y.; Cohen, I.R.; Fuks, Z.; Vlodavsky, I. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood 1987, 70, 551-557.
16. Borsig, L.; Wong, R.; Hynes, R.O.; Varki, N.M.; Varki, A. Synergistic effects of l- and p-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicates leukocytes as enhancers of metastasis. Proc. Natl. Acad. Sci. USA 2002, 99, 2193-2198.
17. Garcia, J.; Callewaert, N.; Borsig, L. P-selectin mediates metastatic progression through binding to sulfatides on tumor cells. Glycobiology 2007, 17, 185-196.
18. Koenig, A.; Norgard-Sumnicht, K.; Linhardt, R.; Varki, A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J. Clin. Invest. 1998, 101, 877-889.
19. Hostettler, N.; Naggi, A.; Torri, G.; Isahai-Michaeli, R.; Casu, B.; Vlodavsky, I.; Borsig, L. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J. 2007, 21, 3562-3572.
20. Bendas, G.; Lubor, B. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int. J. Cell Biol. 2012, doi:10.1155/2012/676731.
21. Nelson, R.M.; Cecconi, O.; Roberts, W.G.; Aruffo, A.; Linhardt, R.J.; Bevilacqua, M.P. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993, 82, 3253-3258.
22. Casu, B.; Vlodavsky, I.; Sanderson, R.D. Non-Anticoagulant Heparins and Inhibition of Cancer. Pathophysiol. Haemost. Thromb. 2007, 36, 195-203.
23. Coombe, D.R.; Kett, W.C. Heparin Mimetics. In Heparin - A Century of Progress, Handbook of Experimental Pharmacology; Lever, R., Mulloy, B., Page, C.P., Eds.; Springer-Verlag: Berlin, Germany, 2012; Volume 207, pp. 361-383.
24. Imberty, A.; Perez, S. Structure, conformation, and dynamics of bioactive oligosaccharides: Theoretical approaches and experimental validations. Chem. Rev. 2000, 100, 4567-4588.
25. Ferro, V.; Fewings, K.; Palermo, M.C.; Li, C. Large-scale preparation of the oligosaccharide phosphate fraction of Pichia holstii NRRL Y-2448 phosphomannan for use in the manufacture of PI-88. Carb. Res. 2001, 332, 183-189.
26. Khachigian, L.M.; Parish, C.R. Phosphomannopentaose Sulfate (PI-88): Heparan Sulfate Mimetic with Clinical Potential in Multiple Vascular Pathologies. Cardiovasc. Drug Rev. 2006, 22, 1-6.
27. Yu, G.; Gunay, N.S.; Linhardt, R.J.; Toida, T.; Fareed, J.; Hoppensteadt, D.A; Shadid, H.; Ferro, V.; Li, C.; Fewings, K.; et al. Preparation and anticoagulant activity of the phosphosulfomannan PI-88. J. Med. Chem. 2002, 37, 783-791.
28. Parish, C.R.; Freeman, C.; Brown, K.J.; Francis, D.J.; Cowden, W.B. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 1999, 59, 3433-3441.
29. Parish, C.R.; Cowden, W.B. Preparation and use of sulfated oligosaccharides. U.S. Patent 6,143,730. US006143730A, 7 November 2000.
30. Guglieri, S.; Hricovíni, M.; Raman, R.; Polito, L.; Torri, G.; Casu, B.; Sasisekharan, R.; Guerrini, M. Minimum FGF2 binding structural requirements of heparin and heparan sulfate oligosaccharides as determined by NMR spectroscopy. Biochemistry 2008, 47, 13862-13869.
31. Guerrini, M.; Guglieri, S.; Santarsiero, R.; Vismara, E. Synthesis and characterisation of hexaand tetrasaccharide mimics from acetobromomaltotriose and acetobromomaltose, and of C-disaccharide mimics from acetobromoglucose, obtained by electrochemical reduction on silver. Tetrahedron: Asymmetry 2005, 16, 243-253.
32. Gong, H.; Gagne, M.R. Diastereoselective Ni-catalyzed Negishi cross-coupling approach to saturated, fully oxygenated C-alkyl and C-aryl glycosides. J. Am. Chem. Soc. 2008, 130, 12177-12183.
33. Carver, J.P. Oligosaccharides: How can flexible molecules act as signals? Pure Appl. Chem. 1993, 65, 763-770.
34. Qasba, P.K. Involvement of sugars in protein-protein interactions. Carbohydr. Polym. 2000, 41, 293-309.
35. Torri, G.; Vismara, E.; Vlodavsky, I.; Naggi, A. Mimetics of sulfated oligosaccharides. Patent PCT/EP2009/058742. WO 2010/006981, A1.
36. Borsig, L.; Vlodavsky, I.; Ishai-Michaeli, R.; Torri, G.; Vismara, E. Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase. Neoplasia 2011, 13, 445-452.
37. Al-Horani, R.A.; Desai, U.R. Chemical sulfation of small molecules - Advances and challenges Tetrahedron 2010, 66, 2907-2918.
38. Ochi, K.; Watanabe, Y.; Okui, K.; Shindo, M. Crystalline salts of sucrose octasulfate. Chem. Pharm. Bull. 1980, 28, 638-641.
39. Kasbauer, C.W.; Paper, D.H.; Franz, G. Sulfated ?-(1→4)-galacto- oligosaccharides and their effect on angiogenesis. Carb. Res. 2001, 330, 427-430.
40. De Paz, J.L.; Noti, C.; Seeberger, P.H. Microarrays of synthetic heparin oligosaccharides. J. Am. Chem. Soc. 2006, 128, 2766-2767.
41. Mestechkina, N.M.; Egorov, A.V.; Shcherbukhin, V.D. Synthesis of galactomannan sulfates. Appl. Biochem. Microbiol. 2006, 42, 326-330.
42. Raghuraman, A; Riaz, M.; Hindle, M.; Desai, U.R. Rapid and efficient microwave-assisted synthesis of highly sulfated organic scaffolds. Tetrahedron Lett. 2007, 48, 6754-6758.
43. Maza, S.; de Paz, J.L.; Nieto, P.M. Microwave-assisted sulfonation of heparin oligosaccharides. Tetrahedron Lett. 2011, 52, 441-443.
44. Krylov, V.B.; Ustyuzhanina, N.E.; Grachev, A.A.; Nifantiev, N.E. Efficient acid-promoted per-O-sulfation of organic polyols. Tetrahedron Lett. 2008, 49, 5877-5879.
45. Krylov, V.B.; Kaskova, Z.M.; Vinnitskiy, D.Z.; Ustyuzhanina, N.E.; Grachev, A.A.; Alexander, O.; Chizhov, A.O.; Nifantiev, N.E. Acid-promoted synthesis of per-O-sulfated fucooligosaccharides related to fucoidan fragments. Carb. Res. 2011, 346, 540-550.
46. Guerrini, M.; Naggi, A.; Guglieri, S.; Santarsiero, R.; Torri, G. Complex glycosaminoglycans: profiling substitution patterns by two dimensional NMR spectroscopy. Anal. Biochem. 2005, 337, 35-47.